Skip to main content

Table 4 Evolution of hemodynamic status from day 1 to day 14

From: Efficacy and safety of ivermectin in the treatment of mild to moderate COVID-19 infection: a randomized, double-blind, placebo-controlled trial

Outcomes

Day 1

Day 7

Day 14

Difference between groupsb

Mean ± SD

Mean ± SD

Mean ± SD

Mean

95%CI

p-value

Temperature (°C)

 Treatment

36.54 ± 0.66

36.40 ± 0.35

36.54 ± 0.24

−0.06

(−0.16 to 0.05)

0.303

 Control

36.65 ± 0.49

36.50 ± 0.30

36.48 ± 0.21

 

Reference

 

p-valuea

0.441

0.176

0.584

   

Heart rate (bpm)

 Treatment

90.86 ± 19.27

76.46 ± 14.82

76.43 ± 16.93

−0.04

(−14 to 0.07)

0.487

 Control

90.63 ± 15.53

75.36 ± 11.66

74.83 ± 10.84

 

Reference

 

p-valuea

0.956

0.730

0.804

   

Systolic blood pressure (mmHg)

 Treatment

135.97 ± 25.54

118.11 ± 15.58

123.86 ± 10.57

1.58

(−3.76 to 6.91)

0.563

 Control

129.69 ± 15.12

122.19 ± 16.30

121.67 ± 10.04

 

Reference

 

p-valuea

0.221

0.285

0.658

   

Diastolic blood pressure (mmHg)

 Treatment

79.49 ± 14.31

72.69 ± 10.32

76.29 ± 11.34

1.08

(−2.55 to 4.72)

0.559

 Control

75.88 ± 12.77

70.50 ± 11.38

69.00 ± 8.29

 

Reference

 

p-valuea

0.282

0.400

0.124

   

Mean arterial pressure (mmHg)

 Treatment

98.31 ± 16.83

87.83 ± 9.97

92.14 ± 9.64

1.25

(−2.58 to 5.08)

0.523

 Control

93.81 ± 11.39

87.73 ± 11.77

86.56 ± 7.67

 

Reference

 

p-valuea

0.201

0.970

0.181

   

Respiratory rate (bpm)

 Treatment

20.06 ± 0.58

19.94 ± 0.34

20.00 ± 0.00

0.03

(−0.08 to 0.13)

0.622

 Control

19.94 ± 0.59

19.89 ± 0.67

19.67 ± 0.78

 

Reference

 

p-valuea

0.421

0.670

0.166

   

Oxygen saturation (%)

 Treatment

97.72 ± 1.23

97.67 ± 1.45

97.75 ± 1.59

−0.11

(−0.53 to 0.31)

0.605

 Control

97.58 ± 1.46

97.75 ± 1.52

97.81 ± 1.21

 

Reference

 

p-valuea

0.664

0.813

0.393

   
  1. aComparison mean at point time between group using independent sample t-test
  2. bMean difference with 95% confidence interval estimated by linear mixed models